GlassScriptPhysician profile
Ashley Wilhelm
NPI 1144803693
$3,223.80
in general payments reported to CMS, 2019-2025
25 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $208 · 2023: $1,043 · 2024: $628 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.19 |
| Education | $378.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $508.87 | 2021-2025 | Sotyktu |
| Abbvie INC. | $445.30 | 2023-2025 | |
| Genzyme Corporation | $319.29 | 2023-2025 | |
| Janssen Biotech, INC. | $313.37 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $207.23 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $202.57 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.78 | 2023 | Dupixent, Libtayo |
| Lilly USA, LLC | $164.37 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Novo Nordisk INC | $124.73 | 2022 | |
| Kyowa Kirin, INC. | $106.26 | 2023-2025 | Poteligeo |
| Pfizer INC. | $97.33 | 2022-2025 | |
| Dermavant Sciences, INC. | $83.48 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Leo Pharma INC. | $72.85 | 2023-2025 | Adbry |
| Ucb, INC. | $70.36 | 2023-2025 | Bimzelx, Cimzia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $48.29 | 2025 | Hadlima, Vtama |
| Galderma Laboratories, L.P. | $35.17 | 2025 | Nemluvio |
| Gilead Sciences, INC. | $33.01 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.45 | 2022 | |
| Incyte Corporation | $23.20 | 2025 | Opzelura |
| Janssen Pharmaceuticals, INC | $20.09 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $19.93 | 2023 | Valchlor |
| Paratek Pharmaceuticals, INC. | $17.50 | 2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $16.80 | 2025 | Acthar |
| Merck Sharp & Dohme LLC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.